AddLife AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
February 02, 2024 at 01:45 am EST
Share
AddLife AB (publ) reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was SEK 2,544 million compared to SEK 2,326 million a year ago. Net loss was SEK 41 million compared to net income of SEK 61 million a year ago. Basic loss per share from continuing operations was SEK 0.34 compared to basic earnings per share from continuing operations of SEK 0.5 a year ago. Diluted loss per share from continuing operations was SEK 0.34 compared to diluted earnings per share from continuing operations of SEK 0.5 a year ago.
For the full year, sales was SEK 9,685 million compared to SEK 9,084 million a year ago. Net income was SEK 190 million compared to SEK 480 million a year ago. Basic earnings per share from continuing operations was SEK 1.56. Diluted earnings per share from continuing operations was SEK 1.56.
AddLife AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company markets and sells instruments, equipment, consumables and related services mainly to the healthcare sector. The Company operates through two segments: The LabTech segment is engaged in the sales of laboratory equipment, analytical instruments and reagents, that are used for diagnostics or biomedical research; The MedTech segment offers various medical device equipment, consumables, instruments and devices, primarily to hospitals. The Company operates through number of subsidiaries, such as BergmanLabora AB, BioNordica group, Holm & Halby A/S, Immuno Diagnostic Oy, LabRobot Products AB, Triolab-group, Active Care Sverup AB, Fenno Medical Oy, Mediplast AB, among others.
ADDLIFE AB 
